Iterum Therapeutics (ITRM) Competitors $0.73 +0.02 (+2.41%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. MCRB, GNLX, BHST, HURA, ALTS, CNTB, FTLF, SKYE, CHRS, and PLXShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Seres Therapeutics (MCRB), Genelux (GNLX), BioHarvest Sciences (BHST), TuHURA Biosciences (HURA), ALT5 Sigma (ALTS), Connect Biopharma (CNTB), FitLife Brands (FTLF), Skye Bioscience (SKYE), Coherus Oncology (CHRS), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Its Competitors Seres Therapeutics Genelux BioHarvest Sciences TuHURA Biosciences ALT5 Sigma Connect Biopharma FitLife Brands Skye Bioscience Coherus Oncology Protalix BioTherapeutics Iterum Therapeutics (NASDAQ:ITRM) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Do analysts recommend ITRM or MCRB? Iterum Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 1,143.09%. Seres Therapeutics has a consensus target price of $73.67, suggesting a potential upside of 406.82%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Iterum Therapeutics is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Does the media prefer ITRM or MCRB? In the previous week, Iterum Therapeutics had 4 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for Iterum Therapeutics and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.13 beat Iterum Therapeutics' score of -0.48 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, ITRM or MCRB? Seres Therapeutics has higher revenue and earnings than Iterum Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.99-0.73Seres Therapeutics$126.32M1.00$140K-$4.60-3.16 Is ITRM or MCRB more profitable? Iterum Therapeutics' return on equity of 0.00% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -71.37% Seres Therapeutics N/A -41,084.76%-55.87% Do institutionals & insiders hold more shares of ITRM or MCRB? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 2.4% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ITRM or MCRB? Iterum Therapeutics has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. SummarySeres Therapeutics beats Iterum Therapeutics on 7 of the 13 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.54M$2.52B$5.55B$9.46BDividend YieldN/A1.78%4.73%4.14%P/E Ratio-0.738.9629.0524.26Price / SalesN/A443.47374.2878.61Price / CashN/A22.2824.4827.20Price / Book-4.834.998.645.80Net Income-$24.77M$31.61M$3.24B$264.73M7 Day Performance-3.47%-1.87%0.23%-1.14%1 Month Performance-23.87%5.80%7.95%5.81%1 Year Performance-36.49%5.30%29.92%23.35% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics1.5993 of 5 stars$0.73+2.4%$9.00+1,131.2%-40.5%$30.80MN/A-0.7410News CoverageEarnings ReportShort Interest ↑High Trading VolumeMCRBSeres Therapeutics2.9748 of 5 stars$13.24-8.9%$73.67+456.4%-40.9%$126.88M$126.32M-2.88330Upcoming EarningsGap UpGNLXGenelux1.1606 of 5 stars$3.39+1.5%$17.75+423.6%+102.9%$126.12M$10K-3.8510Positive NewsBHSTBioHarvest SciencesN/A$7.50-1.1%$13.67+82.2%N/A$124.50M$25.19M-15.00N/ANews CoverageHURATuHURA Biosciences1.2924 of 5 stars$2.78-2.5%$12.67+355.6%N/A$124.49MN/A0.00N/AALTSALT5 SigmaN/A$6.98-1.4%N/A+339.4%$123.58M$12.53M0.00170CNTBConnect Biopharma2.252 of 5 stars$2.08-6.3%$7.00+236.5%+82.1%$123.35M$26.03M0.00110Short Interest ↑Gap DownFTLFFitLife Brands3.5634 of 5 stars$12.83-0.5%$20.50+59.8%-15.5%$121.15M$63.86M15.2720News CoverageGap UpSKYESkye Bioscience1.1886 of 5 stars$3.74-4.3%$16.60+343.9%-33.1%$121.11MN/A-4.5611CHRSCoherus Oncology3.9089 of 5 stars$1.07+2.9%$4.68+337.7%-35.7%$120.57M$266.96M-0.95330Upcoming EarningsGap UpHigh Trading VolumePLXProtalix BioTherapeutics2.426 of 5 stars$1.50-0.7%$15.00+900.0%+42.9%$119.41M$59.76M-11.54200 Related Companies and Tools Related Companies Seres Therapeutics Alternatives Genelux Alternatives BioHarvest Sciences Alternatives TuHURA Biosciences Alternatives ALT5 Sigma Alternatives Connect Biopharma Alternatives FitLife Brands Alternatives Skye Bioscience Alternatives Coherus Oncology Alternatives Protalix BioTherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITRM Stock Alerts